[HTML][HTML] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
S Tanaka, J Uchino - Translational Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
As noted above, other occasional reports have described that the frequency of EGFR
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
S Tanaka, J Uchino - Translational Lung Cancer Research, 2019 - tlcr.amegroups.org
This Chinese randomized, open-label, phase 2 trial compared erlotinib with the standard-of-
care vinorelbine plus cisplatin therapy as adjuvant treatment for patients with stage IIIA …
care vinorelbine plus cisplatin therapy as adjuvant treatment for patients with stage IIIA …
Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer.
S Tanaka, J Uchino - Translational Lung Cancer Research, 2019 - europepmc.org
As noted above, other occasional reports have described that the frequency of EGFR
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
[PDF][PDF] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
S Tanaka, J Uchino - cdn.amegroups.cn
As noted above, other occasional reports have described that the frequency of EGFR
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
mutation-positive lung cancer, response to TKI treatment, and incidence of adverse events …
[引用][C] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
S Tanaka, J Uchino - Translational lung cancer research, 2019 - pubmed.ncbi.nlm.nih.gov